Rezdiffra (Resmetirom) Side Effects: Delayed-Onset Adverse Events Women Should Know

What Is Resmetirom and Why Do Women Use It?

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist approved by the FDA on March 14, 2024 for adults with MASH and moderate-to-advanced liver fibrosis (stages F2 and F3). THR-beta is expressed mainly in the liver. Activating it drives fat breakdown and reduces hepatic triglycerides without the cardiac and bone effects associated with systemic hyperthyroidism through the predominantly cardiac THR-alpha receptor.

Women represent a large share of the MASH population. Postmenopausal women develop MASH at rates that approach or exceed those of age-matched men, largely because estrogen loss reduces hepatic fat oxidation and worsens insulin resistance. Women living with PCOS carry an even earlier risk because hyperinsulinemia drives hepatic de novo lipogenesis from reproductive years onward. Understanding which side effects appear late, not just in the first two weeks, is especially important for women managing multiple chronic conditions and juggling multiple prescriptions.

The Delayed-Onset Side-Effect Problem: Why Timing Matters

Most published adverse-event lists sort by frequency. They do not tell you when an event is likely to appear. That distinction matters clinically: a side effect that starts in week eight looks like a new problem, not a drug reaction, unless you know to watch for it.

Why Some Adverse Events Are Delayed

Resmetirom reaches steady-state plasma concentration in approximately seven days. Genomic effects, meaning changes in hepatic gene transcription driven by THR-beta activation, accumulate over weeks. Liver enzyme shifts reflect structural hepatic remodeling that takes time. Muscle enzyme changes follow altered mitochondrial fatty-acid metabolism that builds gradually. Hormonal feedback loops, particularly the pituitary-thyroid axis, take four to eight weeks to reach a new equilibrium after a pharmacological perturbation.

The MAESTRO-NASH Trial Timeline

The key MAESTRO-NASH trial enrolled 966 adults across 13 countries and ran 52 weeks at doses of 80 mg and 100 mg daily versus placebo. Adverse events were captured prospectively at weeks 4, 8, 12, 24, 36, and 52. Several signals that were statistically distinct from placebo did not reach full expression until weeks 8 through 24. Knowing those windows helps you and your clinician decide whether a new symptom is the drug or something else entirely.

Early Side Effects (Weeks 0-4): The More Familiar Ones

These are well-publicized and appear promptly.

Nausea and Diarrhea

Nausea occurred in approximately 33% of participants on 100 mg in MAESTRO-NASH, compared with 14% on placebo. Diarrhea occurred in roughly 29% on 100 mg versus 17% on placebo. Both peaked in the first two to four weeks and attenuated with time for most participants. Taking resmetirom with food reduces peak plasma concentration and blunts GI symptoms.

Vomiting

Vomiting was reported in about 6% on 100 mg versus 3% on placebo. It rarely caused discontinuation on its own. For women who are also taking GLP-1 receptor agonists (semaglutide, tirzepatide) for concurrent metabolic disease, additive GI effects can be meaningful. Your prescriber should know about any GLP-1 you are on before resmetirom is started.

Delayed-Onset Side Effects (Weeks 4-24 and Beyond)

These signals are less publicized and deserve detailed attention, particularly for women.

Liver Enzyme Elevations (ALT and AST)

Resmetirom targets the liver, so watching liver enzymes throughout the course of therapy is not optional. ALT elevations greater than three times the upper limit of normal occurred in approximately 5-6% of participants on active drug in MAESTRO-NASH. Critically, some of these elevations appeared after week four and continued to evolve through weeks 12 and 24. A few participants had elevations that met criteria for drug-induced liver injury (DILI) evaluation.

What Women With MASH and Other Liver Conditions Need to Know

Women with autoimmune hepatitis, primary biliary cholangitis (PBC), or concurrent hepatotoxic drug use (methotrexate, amiodarone, certain antifungals) are at compounded risk. The FDA label recommends obtaining baseline liver tests and monitoring at weeks 4, 8, and 12, then periodically thereafter. If ALT rises to more than five times the upper limit of normal, the drug should be stopped and not restarted without specialist review.

The MASH Paradox

Here is a complication specific to this drug's mechanism: resmetirom actively reduces hepatic fat and promotes fibrosis regression, which can itself cause transient enzyme shifts as the liver remodels. Distinguishing beneficial remodeling from true hepatotoxicity requires clinical context, not just a lab number in isolation.

Thyroid Hormone Axis Changes

THR-beta is expressed in both the liver and pituitary. Because resmetirom activates pituitary THR-beta as well, it suppresses TSH. In MAESTRO-NASH, TSH decreased by a mean of approximately 0.3 mIU/L from baseline in the treated arms, with the nadir typically reached between weeks 8 and 16, not in the first month.

Why This Is a Women's Health Issue Specifically

Women are five to ten times more likely than men to have autoimmune thyroid disease. An estimated 10-15% of perimenopausal and postmenopausal women already take levothyroxine for hypothyroidism. Resmetirom-driven TSH suppression in a woman on a fixed levothyroxine dose can shift her from euthyroid to subclinically hyperthyroid within eight to twelve weeks of starting the drug. Symptoms, palpitations, poor sleep, heat intolerance, and anxiety, can mimic perimenopausal vasomotor symptoms exactly, making attribution genuinely difficult without a TSH check.

The practical framework for women on thyroid replacement:

1. Get a baseline TSH and free T4 before starting resmetirom.
2. Recheck TSH at week 8 and again at week 16.
3. If TSH falls below 0.5 mIU/L, discuss levothyroxine dose reduction with your prescriber before symptoms appear.
4. Do not adjust levothyroxine on your own based on symptoms alone during the first four months of resmetirom therapy.

Women with Hashimoto thyroiditis who are not yet on levothyroxine should still have baseline and follow-up TSH monitoring because subclinical disease can be unmasked.

Cholelithiasis (Gallstones) and Biliary Events

Thyroid hormone receptor agonism increases bile acid secretion and alters cholesterol metabolism, which raises the theoretical risk of gallstone formation. The MAESTRO-NASH 52-week data showed cholelithiasis in a small percentage of active-drug participants, with most cases identified after week 12. Women already have a higher baseline risk of gallstones than men at every age, and obesity and rapid weight loss (which resmetirom can contribute to through fat reduction) further increase that risk.

Symptoms to report: right upper quadrant pain, particularly after fatty meals, nausea distinct from the early GI profile, or fever with jaundice. Ultrasound is the diagnostic tool of choice.

Muscle-Related Signals: Myalgia and CK Elevation

Resmetirom alters mitochondrial fatty-acid oxidation in skeletal muscle, a secondary site of THR-beta expression. In MAESTRO-NASH, myalgia was reported at a slightly higher rate in treated participants than in placebo, with many cases presenting after weeks 6 to 10. Creatine kinase (CK) elevations of more than five times the upper limit of normal were rare but did occur. The FDA label does not yet require routine CK monitoring, but the label does instruct clinicians to evaluate unexplained muscle pain or weakness.

Women on concurrent statins (common in the MASH population given overlapping cardiovascular risk) should know that statin-associated myopathy and resmetirom-associated myalgia can be additive. If you develop new muscle pain after starting resmetirom, tell your prescriber rather than waiting for your next scheduled visit.

Pruritus (Itching) as a Delayed Signal

Pruritus was reported in a small percentage of participants and, unlike GI events, often appeared after week four rather than in the first days of therapy. The mechanism is incompletely understood but may relate to altered bile acid composition. Women with a history of intrahepatic cholestasis of pregnancy or PBC may have heightened susceptibility, though direct data in these subgroups are absent from MAESTRO-NASH.

Blood Lipid Changes: Good News With a Caveat

Resmetirom consistently reduces LDL cholesterol and triglycerides. In MAESTRO-NASH, LDL fell by approximately 16% from baseline on 100 mg at week 52. This is broadly positive, but it means that if you are on a statin dose that was calibrated to your pre-resmetirom lipid panel, your statin may now be more than you need, which could contribute to myopathy risk. A repeat lipid panel at 12 weeks is reasonable.

Rare Side Effects: What the FAERS Data Add

The FDA Adverse Event Reporting System (FAERS) captures post-market signals that trials may not. Resmetirom has only been commercially available since mid-2024, so FAERS data are still accumulating. Early post-market signals under review include:

• Hepatic failure reports in patients with more advanced fibrosis than the F2-F3 population studied in MAESTRO-NASH.
• Rare reports of significant TSH suppression (<0.1 mIU/L) with thyrotoxic symptoms in women with pre-existing thyroid nodules or previously undiagnosed Graves disease.
• Isolated cases of severe diarrhea leading to dehydration in women who began resmetirom while also taking GLP-1 agonists.

These are signals, not confirmed causal associations. The rarity makes formal incidence estimates premature. The FDA drug label will be updated as post-market data mature.

Who This Drug Is Right For, and Who Should Pause

Women Who May Benefit Most

• Postmenopausal women with biopsy-confirmed MASH, F2 or F3 fibrosis, and LDL above goal despite statin therapy. Resmetirom's lipid-lowering effect is a genuine co-benefit.
• Women with PCOS and concurrent MASH who have not achieved adequate hepatic improvement through lifestyle and metformin alone. PCOS-associated MASH appears at younger ages and higher BMIs than MASH in the general population.
• Women in reproductive years who need effective contraception anyway for metabolic reasons and can commit to a reliable method.

Women Who Should Exercise Caution or Avoid It

• Women with thyroid cancer history or active Graves disease. THR-beta selectivity does not guarantee thyroid safety in these contexts, and there are no data specific to these populations.
• Women with gallbladder disease or a prior cholecystectomy. Biliary effects may be more symptomatic without a functioning gallbladder.
• Women on hepatotoxic medications who cannot discontinue them. Stacking liver risks is not advised.
• Women who are pregnant or planning pregnancy within the next treatment cycle (see below).

Pregnancy, Lactation, and Contraception: A Required Section

Resmetirom is contraindicated in pregnancy. This is not a relative caution. The FDA label classifies it as a drug that may cause fetal harm based on animal reproductive toxicity data. In animal studies, resmetirom caused embryo-fetal death and structural abnormalities at exposures relevant to human therapeutic doses.

What This Means Practically

Women of reproductive potential must use effective contraception throughout therapy. The label does not specify a minimum washout period before attempting conception, but given resmetirom's half-life of approximately six days and its genomic mechanism, most specialists are advising at least one month after stopping before trying to conceive. Discuss this timeline explicitly with your prescriber before starting.

Lactation

It is not known whether resmetirom is present in human breast milk. Animal data suggest it is excreted in milk. Because of the potential for serious adverse effects in a nursing infant, the FDA label advises that women should not breastfeed during resmetirom therapy and for a period after the final dose. The specific post-dose interval is not yet defined with precision in the label; ask your clinician to check the most current labeling language.

Perimenopause and Contraception

Women in perimenopause often assume they cannot conceive. Perimenopause does not mean infertility. Unintended pregnancy remains possible until 12 months after the final menstrual period for women over 50, or 24 months for women under 50 by most clinical conventions. ACOG recommends that perimenopausal women continue contraception until menopause is confirmed. If you are perimenopausal and starting resmetirom, clarify your contraceptive status with your provider.

Sex-Specific Pharmacokinetics: What We Know and What We Do Not

The resmetirom label reports that sex did not significantly affect pharmacokinetics in population PK analyses from MAESTRO-NASH. However, the label also acknowledges that body weight and concomitant medications influence exposure, and women in the trial were on average smaller than men, meaning weight-based exposure variation is real. The MAESTRO-NASH enrollment was approximately 49% female, which is better than many drug trials, but the published subgroup analyses by sex for adverse-event rates have not been reported in the primary paper.

This is an evidence gap. The delayed-onset side effects described here, particularly thyroid axis suppression and gallstone formation, are biologically more relevant to women than to men based on background risk, but sex-stratified safety data from the trial have not been published as of this writing. WomanRx will update this article when that analysis is available.

Monitoring Schedule for Women on Resmetirom

| Time Point | Lab or Assessment | Reason | |---|---|---| | Baseline | ALT, AST, bilirubin, TSH, free T4, lipid panel, CK if on a statin, urine or serum pregnancy test | Safety baseline and contraception confirmation | | Week 4 | ALT, AST | Early hepatotoxicity screen per label | | Week 8 | ALT, AST, TSH | Thyroid nadir window begins | | Week 12 | ALT, AST, lipid panel | Full hepatic and metabolic reassessment | | Week 16 | TSH, free T4 | Thyroid equilibration confirmation | | Week 24 | ALT, AST, TSH, gallbladder ultrasound if symptomatic | Mid-course safety review | | Week 52 | Full metabolic panel, liver biopsy or non-invasive fibrosis marker | Efficacy and safety assessment |

This schedule is derived from the MAESTRO-NASH monitoring protocol and the FDA label. Your clinician may adjust it based on your individual history.

Drug Interactions Relevant to Women

Women with MASH often carry concurrent diagnoses that come with their own drug lists. Resmetirom is metabolized primarily by CYP2C8 and is a substrate and inhibitor of certain transporters.

• Oral contraceptives: Ethinyl estradiol is a CYP substrate, and while no direct interaction study with resmetirom has been published, the label advises caution with hepatic transporter-sensitive drugs. Discuss your contraceptive method with your prescriber.
• Statins: Resmetirom inhibits OATP1B1 and OATP1B3, transporters that mediate hepatic statin uptake. Co-administration with rosuvastatin or pravastatin increases statin exposure. The label recommends dose caps for certain statins used concurrently with resmetirom.
• Levothyroxine: No pharmacokinetic interaction, but pharmacodynamic overlap at the pituitary level (see thyroid section above) makes dose adjustment likely for some women.
• GLP-1 receptor agonists: No formal interaction data, but additive GI effects are clinically reported.

What Symptom Patterns Should Prompt You to Call Your Clinician Right Away

Do not wait for your next scheduled appointment if you experience:

• Jaundice (yellowing of skin or whites of eyes), dark urine, or severe right-sided abdominal pain.
• Heart palpitations, heat intolerance, or unexplained weight loss starting weeks after you began the drug (possible delayed thyrotoxicosis).
• Severe or worsening muscle pain, especially if accompanied by dark or tea-colored urine (possible rhabdomyolysis, though rare).
• Any possible pregnancy symptoms. Stop the drug and test immediately.

Mild nausea or diarrhea in the first few weeks does not require an urgent call unless you cannot stay hydrated.